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AbstrAct
Objectives tofacitinib is an oral Janus kinase 
inhibitor for treatment of psoriatic arthritis (Psa). 
Patient-reported outcomes (PrOs) were evaluated 
in patients with Psa with inadequate responses 
to tumour necrosis factor inhibitors (tnFi-ir) in a 
6-month, phase iii randomised controlled trial (OPal 
Beyond [nct01882439]).
Methods Patients (n=394) received tofacitinib 5 or 
10 mg twice daily or placebo (advancing to tofacitinib 
5 or 10 mg twice daily at month 3). least squares 
mean changes from baseline and percentages of 
patients reporting improvements ≥minimum clinically 
important differences and scores ≥normative values 
were determined in Patient global assessment of 
disease activity (Ptga), Pain, Patient global Joint 
and Skin assessment (PgJS), Short Form-36 Health 
Survey version 2 (SF-36v2), Functional assessment 
of chronic illness therapy-Fatigue (Facit-Fatigue), 
euroQol 5-Dimensions-3-level (eQ-5D-3l), eQ-VaS and 
ankylosing Spondylitis Quality of life (aSQol). nominal 
p values are without multiple comparison adjustments.
Results at month 3, Ptga, Pain, PgJS, SF-36v2 
Physical component Summary (PcS), physical 
functioning (PF), bodily pain (BP), vitality and social 
functioning (SF) domains, Facit-Fatigue total score, 
eQ-5D-3l pain/discomfort, eQ-VaS and aSQol scores 
exceeded placebo with both tofacitinib doses (role 
physical [rP] with 10 mg twice daily only; p≤0.05). 
Patients reporting improvements ≥MciD (%) in Ptga, 
PgJS, Pain, aSQol and SF-36v2 PcS, PF, rP, BP, SF 
(both tofacitinib doses) exceeded placebo (p≤0.05).
Conclusion tnFi-ir patients with Psa receiving 
tofacitinib reported statistically and clinically 
meaningful improvements in PrOs versus placebo over 
3 months, which were maintained to month 6. Despite 
lower baseline scores, these improvements were 
similar to the csDMarD-ir tnFi-naive OPal Broaden 
trial.
InTROduCTIOn
Psoriatic arthritis (PsA), a chronic inflam-
matory disease, causes pain and swelling in 
the joints,1 and is associated with consider-
able impairment in physical function and 
health-related quality of life (HRQoL).2–4
Key messages
What is already known about this subject?
 ► the efficacy and safety of tofacitinib 5 and 10 mg 
twice daily in patients with psoriatic arthritis (Psa) 
have been demonstrated in two phase iii randomised 
controlled trials (rcts).
 ► Patient-reported outcomes (PrOs), measuring Psa-
specific skin and joint disease activity, are included 
in the domains to be assessed in Psa rcts recom-
mended by group for research and assessment 
of Psoriasis and Psoriatic arthritis and Outcome 
Measures in rheumatology and complement physi-
cian assessments and laboratory measures of dis-
ease activity.
What does this study add?
 ► this post-hoc analysis of patients with Psa and an 
inadequate response to tumour necrosis factor in-
hibitors (tnFi-ir) reported significant improvements, 
exceeding placebo, across a range of PrOs, demon-
strating that tofacitinib not only treats the signs and 
symptoms of Psa, but can also improve patient func-
tion and quality of life.
 ► these improvements were reported for both tofaci-
tinib doses within 2–4 weeks and were maintained 
to month 6.
How might this impact on clinical practice?
 ► tofacitinib may be used to improve PrOs in tnFi-ir 
patients with Psa.
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PsA-specific measures such as skin and joint disease 
activity, and pain, can be assessed using a number of 
patient-reported outcomes (PROs): Patient Global 
Assessment of disease activity (PtGA) and/or Patient 
Global Joint and Skin Assessment (PGJS),5 Health Assess-
ment Questionnaire Disability Index (HAQ-DI),6 Func-
tional Assessment of Chronic Illness Therapy-Fatigue 
(FACIT-Fatigue), the generic Short Form-36 Health 
Survey version 2 (SF-36v2),7 EuroQol 5-Dimensions-3-
level (EQ-5D-3L),8 disease-specific Ankylosing Spondylitis 
Quality of Life (ASQoL)9 and Dermatology Life Quality 
Index (DLQI).10 Several of these instruments assess the 
core set of domains, outlined by the Group for Research 
and Assessment of Psoriasis and Psoriatic Arthritis (GRAP-
PA)-Outcome Measures in Rheumatology (OMERACT) 
PsA working group recommendations, which are to be 
assessed in all PsA randomised controlled trials (RCTs) 
and longitudinal observational studies.11 The develop-
ment of these recommendations also included patient 
focus groups, reflecting the importance of PROs to both 
clinician and patients. Another GRAPPA-OMERACT 
initiative has found that several of the above instruments 
(eg, HAQ-DI) demonstrate evidence of reliability and 
validity in the measurement of PROs in PsA.12
Tofacitinib is an oral Janus kinase (JAK) inhibitor for 
the treatment of PsA. The efficacy and safety of tofaci-
tinib 5 and 10 mg twice daily have been demonstrated in 
two phase III RCTs of 6 to 12 months’ duration in patients 
with an inadequate response to conventional synthetic 
disease-modifying antirheumatic drugs (csDMARD-IR) 
or tumour necrosis factor inhibitors (TNFi-IR) with active 
PsA (OPAL Beyond: NCT01882439; OPAL Broaden: 
NCT01877668),13 14 and in an ongoing long-term exten-
sion study (OPAL Balance: NCT01976364).
Minimum clinically important differences (MCIDs) are 
key concepts in determining if changes due to treatment 
are not only significant, but also clinically meaningful to 
patients, based on improvements reported in patients’ 
global assessment of disease activity.15 While various 
other methods have also been developed to assess clini-
cally important differences,16–18 in this trial we evaluated 
the percentage of patients reporting previously defined 
improvements ≥MCID at month 3 in each treatment group. 
This is in line with previously reported phase III RCTs in 
patients with PsA.19 We also compared the percentages of 
patients with scores ≥normative values, at month 3 in each 
treatment group.
The objective of these analyses was to evaluate the 
effect of tofacitinib treatment on PROs in patients with 
PsA who were TNFi-IR from the OPAL Beyond RCT.
MeTHOds
study design
OPAL Beyond was a phase III RCT conducted in 98 
centres worldwide, between June 2013 and April 2016. 
Eligible patients were ≥18 years old (≥20 years in Taiwan); 
TNFi-IR; with a diagnosis of PsA for ≥6 months; fulfilled the 
ClASsification criteria for Psoriatic ARthritis (CASPAR),20 
with active plaque psoriasis at screening and active arthritis 
(≥3 swollen and ≥3 tender joints) at screening and base-
line. Exclusion criteria were as previously reported.
Eligible patients were randomised 2:2:1:1 to receive 
tofacitinib 5 mg twice daily, tofacitinib 10 mg twice 
daily, placebo advanced to tofacitinib 5 mg twice daily 
or placebo advanced to tofacitinib 10 mg twice daily. 
Placebo groups advanced in a blinded manner to tofac-
itinib at month 3. All patients continued treatment with 
a stable dose of a single csDMARD, the most frequent 
being methotrexate.
Assessment of PROs
PROs were assessed up to month 6. MCIDs values 
were defined as mean improvements from baseline to 
month 3 in a treatment group, based on previously 
published data.7 21
PtGA by visual analogue scale (VAS, mm), Pain-VAS 
and HAQ-DI13 were evaluated at baseline, week 2 and 
months 1, 2, 3, 4 and 6.5 22
Additionally, the following were evaluated at base-
line, months 1, 3 and 6 and the percentages of patients 
reporting improvements ≥MCID analysed7 19 21 23–26: PGJS 
as a combined global score, and separate joint and skin 
scores, due to the potential divergence in the self-assess-
ment of joint and skin disease activities5; SF-36v2 Physical 
Component Summary (PCS) and Mental Component 
Summary (MCS) and eight (norm-based) domain scores 
(physical functioning [PF], role physical [RP], bodily 
pain [BP], general health [GH], vitality [VT], social 
functioning [SF], role emotional [RE], mental health 
[MH])7; FACIT-Fatigue Total score27; EQ-5D-3L dimen-
sion scores; overall health state (evaluated using EuroQol 
Health State-VAS [EQ-VAS])8 and ASQoL.9 The ranges 
and cut-offs for these values are detailed in the online 
supplementary material 1.
PtGA, Pain, SF-36v2, EQ-5D-3L, FACIT-Fatigue and 
ASQoL were secondary outcome measures and SF-36v2 
PF domain and FACIT-Fatigue were predefined secondary 
efficacy endpoints at Month 3. HAQ-DI responses have 
been reported previously.13
statistical analysis
For continuous endpoints, least squares mean changes 
from baseline were compared between tofacitinib (5 and 
10 mg twice daily) versus placebo for time points up to 
month 3 using a repeated-measures model with the fixed 
effects of treatment, visit, treatment-by-visit interaction, 
geographic location and baseline values, without imputa-
tion for missing values. The two placebo sequences were 
combined into a single placebo group as the placebo-con-
trolled period ended at month 3. Results after month 3 
were generated using a second repeated-measures model 
with two placebo sequences modelled separately.
For binary endpoints, p values were calculated for 
comparing percentages between treatment groups, 
based on the normal approximation for the difference 
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in binomial percentages. The same method was used to 
analyse the percentages of patients reporting normative 
values (defined in the online supplementary material 
1). Missing values were not imputed, except for HAQ-DI 
response based on MCID, where non-responder imputa-
tion was prespecified for this efficacy measure. Nominal 
p values for the difference between tofacitinib (5 and 
10 mg twice daily) versus placebo were reported without 
adjustment for multiplicity. For all endpoints, significance 
level was set at p≤0.05 throughout.
For each outcome and treatment comparison, the stan-
dardised response mean (SRM) was calculated as the 
ratio of the difference in mean changes from baseline 
between treatment groups to the pooled SD of change 
scores (across all three groups).28 29 These standardised 
treatment differences are represented in SD units with 
<0.20 taken as ‘trivial’, 0.20 ‘small’, 0.50 ‘medium’ and 
0.80 ‘large’ treatment effects.30
For illustrative purposes and to facilitate viewing 
improvements in HRQoL simultaneously across eight 
domains,31 spydergrams were generated using SF-36v2 
domain raw scores (range: 0–100; age-gender norms 
matched to study population).
Based on responses ≥MCID, numbers needed to treat 
(NNT) were calculated, defined as the inverse of the 
difference between PRO response rates in tofacitinib and 
placebo groups at month 3. A separate benchmark anal-
ysis included the percentages of patients reporting scores 
≥normative values, with ‘normative’ referring to scores in 
the US general population, without chronic disease.
Pearson correlation coefficients (|r|) were assessed 
at month 3 with particular interest in HAQ-DI and 
SF-36v2 PF domain; Pain (VAS) and SF-36v2 BP domain 
and EQ-5D-3L pain/discomfort dimension; correla-
tions between FACIT-Fatigue Total score and SF-36v2 
VT domain are to be published in a future publication. 
Statistical significance for testing the null hypothesis of 
Pearson correlations equal to zero was calculated based 
on Student’s t distribution.
ResulTs
Patient demographics and baseline characteristics
Baseline patient demographics, reported previously, were 
broadly similar across treatment groups.13
In total, 131 and 132 patients received tofacitinib 5 
and 10 mg twice daily, respectively, and 131 placebo 
patients advanced to tofacitinib treatment at month 3. 
The majority of patients were Caucasian (92.1%), female 
(55.3%), with a mean age of 50.0 (SD 12.0 years) and 
mean disease duration of 9.1–9.6 years. Baseline disease 
characteristics were similar across treatment groups, 
except for mean tender joint count, which was highest 
in the tofacitinib 10 mg twice daily group. The average 
number of TNFi previously used was 1.5–1.7 across treat-
ment groups and 11%–14% of patients had previously 
used biological DMARDs other than TNFi.13
PROs
Baseline PRO scores were comparable across treatment 
groups (table 1). Significant improvements from baseline 
were reported at month 3 with both doses of tofacitinib 
compared with placebo in PtGA; Pain; HAQ-DI; PGJS; 
SF-36v2 PCS and four SF-36v2 domain scores (PF, BP, 
VT, SF); FACIT-Fatigue; EQ-5D-3L pain/discomfort and 
health state (EQ-VAS); and ASQoL (all p≤0.05; table 1). 
Patients receiving tofacitinib 10 mg twice daily reported 
improvements in SF-36v2 RP domain versus placebo 
(tofacitinib 10 mg p≤0.05; table 1). Numerically greater 
improvements were reported in all EQ-5D-3L dimen-
sions compared with placebo, except for usual activities 
(similar for all groups).
SRMs of the results shown in table 1 (data not shown) 
suggest that the magnitude of treatment effect falls into 
four categories: (1) medium effect (SRM ~0.50; PtGA-VAS; 
Pain-VAS; PGJS-VAS arthritis, psoriasis; SF-36v2 BP), (2) 
small-to-medium effect (SRM, 0.2–0.5; HAQ-DI; SF-36v2 
PCS, PF, RP, SF; FACIT-Fatigue Total score, experience, 
impact; EQ-5D-3L pain/discomfort; EQ-VAS), (3) small 
effect (SRM ~0.2; SF-36v2, GH, VT, MH; EQ-5D-3L mobility, 
self-care, usual activities) and (4) trivial effect (SRM <0.2; 
SF-36v2 MCS, RE; EQ-5D-3L usual activities, anxiety/
depression).
PtGA, Pain and PGJs
Significantly greater improvements from baseline, 
compared with placebo, were apparent for both tofacitinib 
doses at the first post-baseline assessment for PtGA and Pain 
(week 2; all p≤0.05; figure 1A,B), and PGJS (month 1; both 
doses p<0.001; figure 1C). Improvements from baseline in 
these endpoints were maintained through month 6. These 
improvements were reflected in patients advancing from 
placebo to tofacitinib 5 or 10 mg twice daily, who reported 
similar improvements after month 3.
The percentages of patients reporting improvements 
in PtGA, Pain and PGJS ≥MCID were significantly higher 
in patients receiving tofacitinib 5 or 10 mg twice daily 
compared with placebo (figure 2). NNT values were 
generally similar for both tofacitinib doses (figure 2).
sF-36v2 PCs and MCs and domain scores
Patients receiving tofacitinib 5 or 10 mg twice daily 
reported improved SF-36v2 PCS scores compared with 
placebo at month 1, maintained to month 3 (all p≤0.01; 
figure 3A). Patients who advanced from placebo to tofac-
itinib 5 or 10 mg twice daily reported similar improve-
ments in SF-36v2 after month 3. No improvements in 
SF-36v2 MCS were reported at month 3 (table 1).
Significant improvements in SF-36v2 domains PF, BP, 
VT and SF domain scores were reported at month 3 with 
both doses of tofacitinib (all p≤0.05; table 1). In addition, 
improvements in RP were reported following tofacitinib 
10 mg twice daily at month 3 compared with placebo 
(p≤0.05; table 1).
Spydergrams of SF-36v2 domains on a 0–100 scale are 
shown in figure 3B. At month 3, similar improvements 
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Table 1 Mean baseline values and LSM changes from baseline to month 3 for PROs
Baseline, mean (SD) Month 3 LSM change from baseline (SE)
Tofacitinib










5 mg twice daily
(N=131)
Tofacitinib





PtGA-VAS (mm) 57.42 (22.89) 58.52 (22.26) 55.76 (23.73) −21.59 (2.23)*** −19.88 (2.25)*** −7.14 (2.25)
Pain-VAS (mm) 56.35 (24.13) 59.45 (22.30) 54.91 (25.27) −21.66 (2.16)*** −20.88 (2.19)*** −7.72 (2.18)
HAQ-DI 1.26 (0.69) 1.37 (0.61) 1.25 (0.76) −0.39 (0.05)*** −0.35 (0.05)*** −0.14 (0.05)
PGJS-VAS (mm) 
  Arthritis and psoriasis 65.37 (21.31) 68.16 (21.31) 62.85 (24.38) −26.35 (2.17)*** −28.22 (2.22)*** −10.56 (2.21)
  Arthritis 66.62 (20.61) 67.88 (22.41) 62.65 (24.62) −25.11 (2.25)*** −26.69 (2.29)*** −11.48 (2.29)
  Psoriasis 53.50 (29.54) 58.88 (29.38) 54.63 (28.69) −22.42 (2.29)*** −27.61 (2.34)*** −7.65 (2.33)
SF-36v2 PCS score 33.57 (8.46) 31.73 (8.93) 34.70 (9.55) 5.18 (0.68)*** 5.34 (0.69)*** 1.77 (0.69)
SF-36v2 MCS score 39.76 (12.64) 39.84 (12.28) 40.59 (12.66) 4.94 (0.88) 4.28 (0.88) 2.97 (0.88)
SF-36v2 norm-based domain scores 
  PF 33.45 (10.43) 32.12 (9.87) 34.03 (10.99) 5.00 (0.72)** 4.08 (0.73)* 1.69 (0.73)
  RP 34.63 (10.34) 32.69 (9.25) 35.86 (10.69) 4.99 (0.81) 5.44 (0.81)* 2.85 (0.81)
  BP 33.24 (7.88) 32.63 (6.94) 35.42 (8.73) 7.00 (0.79)*** 7.59 (0.80)*** 2.10 (0.80)
  GH 34.71 (8.71) 33.53 (9.29) 35.60 (10.09) 3.67 (0.64) 3.92 (0.65) 2.45 (0.65)
  VT 39.70 (10.22) 38.51 (9.02) 40.25 (10.73) 4.95 (0.83)* 4.75 (0.84)* 2.41 (0.84)
  SF 36.46 (11.47) 35.26 (11.12) 37.56 (11.81) 6.25 (0.84)** 5.46 (0.86)* 2.89 (0.86)
  RE 35.50 (13.95) 35.49 (13.49) 36.03 (14.12) 5.44 (1.00) 4.84 (1.00) 3.85 (1.00)
  MH 38.33 (11.84) 38.90 (10.97) 40.19 (12.45) 4.36 (0.85) 4.11 (0.87) 2.11 (0.87)
FACIT-Fatigue 
  Total score 26.1 (12.15) 26.1 (10.27) 27.5 (11.58) 7.0 (0.81)*** 5.8 (0.82)* 3.0 (0.82)
  Experience domain score 8.2 (5.07) 8.1 (4.29) 8.6 (4.80) 3.1 (0.38)** 2.6 (0.39)* 1.5 (0.39)
  Impact domain score 17.8 (7.56) 18.0 (6.48) 18.9 (7.36) 3.9 (0.48)*** 3.2 (0.49)* 1.6 (0.49)
EQ-5D-3L dimension scores 
  Mobility 1.68 (0.47) 1.78 (0.42) 1.71 (0.46) −0.17 (0.04)* −0.15 (0.04) −0.05 (0.04)
  Self-care 1.46 (0.50) 1.61 (0.49) 1.50 (0.56) −0.15 (0.04) −0.15 (0.04) −0.04 (0.04)
  Usual activities 1.91 (0.46) 1.98 (0.43) 1.92 (0.49) −0.23 (0.04) −0.22 (0.04) −0.15 (0.04)
  Pain/discomfort 2.24 (0.46) 2.27 (0.46) 2.21 (0.46) −0.32 (0.04)** −0.29 (0.04)** −0.12 (0.04)
  Anxiety/depression 1.69 (0.60) 1.73 (0.57) 1.73 (0.71) −0.19 (0.04) −0.20 (0.05) −0.12 (0.05)
  EQ-VAS (mm) 51.98 (22.30) 48.83 (21.49) 53.39 (22.34) 8.62 (1.85)* 12.33 (1.90)*** 2.64 (1.90)
ASQoL 11.4 (4.83)  12.2 (4.45)  10.7 (5.20)  −3.8 (0.38)***  −3.5 (0.39)***  −1.5 (0.40)
N is the number of patients per group in the Full Analysis Set; the number of patients evaluable for each baseline characteristic may be 
fewer than N.
*p≤0.05, **p<0.01, ***p<0.001 compared with placebo; results at month 3 were based on a repeated -measures model including data 
up to month 3 for tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily and combined placebo group without imputation for missing 
values.
ASQoL, Ankylosing Spondylitis Quality of Life; BP, bodily pain; EQ-5D-3L, EuroQol 5-Dimensions-3-level; EQ-VAS, EuroQol Health State 
visual analogue scale; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy-Fatigue; GH, general health; HAQ-DI, Health 
Assessment Questionnaire Disability Index; LSM, least squares mean; MCS, Mental Component Summary; MH, mental health;  
PCS, Physical Component Summary; PF, physical functioning; PGJS, Patient Global Joint Skin Assessment; PRO, patient-reported 
outcome; PtGA, Patient Global Assessment of disease activity; RE, role emotional; RF, role physical; SF, social functioning;  
SF-36v2, Short Form-36 Health Survey version 2; VAS, visual analogue scale; VT, vitality.
from baseline were reported for GH, RE and MH for all 
groups, with greater improvements in all other SF-36v2 
domains with both tofacitinib doses compared with 
placebo, except RP, superior to placebo only with tofaci-
tinib 10 mg twice daily.
The percentages of patients reporting improvements 
≥MCID at month 3 were significantly higher with both 
tofacitinib doses compared with placebo in SF-36v2 
PCS, and PF, RP, BP and SF (figure 2). The percent-
ages of patients reporting scores ≥normative values were 
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Figure 1 Least squares mean (LSM) changes from baseline: (A) Patient Global Assessment of disease activity visual analogue 
scale (PtGA-VAS) (mm); (B) Pain-VAS (mm); (C) Patient Global Joint and Skin Assessment (PGJS-VAS) (mm) arthritis and 
psoriasis. *p≤0.05, **p<0.01, ***p<0.001 compared with placebo; results up to month 3 were based on a repeated-measures 
model including data up to month 3 for tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily and combined placebo 
group. Results after month 3 were based on a second repeated-measures model including data up to end of study for the four 
treatment sequences (tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily, placebo → tofacitinib 5 mg twice daily and 
placebo → tofacitinib 10 mg twice daily), reporting results after month 3 only. Missing values were not imputed. N is number of 
patients evaluable at each visit. BID, twice daily.
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Figure 2 Percentages of patients reporting improvements from baseline ≥minimum clinically important difference (MCID) 
and numbers needed to treat (NNTs) in (A) patient-reported outcomes (PROs), (B) Short Form-36 Health Survey version 2 
(SF-36v2) domain scores; and percentages of patients reporting scores ≥normative values in (C) PROs; (D) SF-36v2 domain 
scores, at month 3. *p≤0.05; **p<0.01; ***p<0.001 compared with placebo; p values were based on the normal approximation 
for the difference in binomial percentages without imputation for missing values (except Health Assessment Questionnaire 
Disability Index [HAQ-DI] MCID response, which used non-responder imputation); N is the number of patients per group in the 
Full Analysis Set; the number of patients evaluable for each PRO endpoint may be fewer than N; MCID cut-offs: Patient Global 
Assessment of disease activity visual analogue scale (PtGA-VAS) decrease from baseline ≥10 mm; Pain-VAS decrease from 
baseline ≥10 mm; Patient Global Joint and Skin Assessment (PGJS)-VAS decrease from baseline ≥10 mm; SF-36v2: Physical 
Component Summary (PCS) and Mental Component Summary (MCS) increase from baseline ≥2.5, SF-36v2 domain scores 
increase from baseline ≥5.0; Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) increase from baseline 
≥4.0; ASQoL decrease from baseline ≥1.8; HAQ-DI decrease from baseline ≥0.35; MCIDs are defined here in terms of mean 
change from baseline to month 3 in a treatment group; NNT calculated by the inverse of the percentage of patients receiving 
tofacitinib reporting improvements ≥MCIDs minus the percentage of patients in the placebo group reporting improvements 
≥MCIDs; the percentage of patients reporting scores ≥normative values: HAQ-DI <0.25, FACIT-Fatigue ≥40.1, SF-36v2 each of 
the component summary and domain scores ≥50. ASQoL, Ankylosing Spondylitis Quality of Life; BID, twice daily; BP, bodily 
pain; GH, general health; MH, mental health; NA, not available; PF, physical functioning; RE, role emotional; RP, role physical; 
SF, social functioning; VT, vitality.
numerically higher with both tofacitinib doses compared 
with placebo for most domains (figure 2). Significantly 
more patients receiving tofacitinib 5 mg twice daily 
reported scores ≥normative values in BP compared with 
placebo. NNTs were similar for tofacitinib doses and <10 
in SF-36v2 PCS, PF, RP, BP and SF (figure 2).
FACIT-Fatigue Total score and AsQol
Patients reported improved FACIT-Fatigue Total scores 
compared with placebo in both tofacitinib doses at 
month 1 (earliest time point), maintained to months 3 
(all p≤0.05; figure 4A) and 6. Patients advancing from 
placebo to tofacitinib 5 or 10 mg twice daily reported 
similar improvements after month 3 (figure 4A). While 
numerically higher compared with placebo, there was 
no significant difference between the percentages of 
patients reporting improvements in FACIT-Fatigue Total 
score ≥MCID in tofacitinib-treated patients (figure 2). 
Patients reporting scores ≥normative values were similar 
for tofacitinib and placebo (figure 2). NNT values were 
lower in patients receiving tofacitinib 5 mg twice daily 
compared with tofacitinib 10 mg twice daily (figure 2).
Improvements in ASQoL exceeded placebo at 
month 1 with both doses of tofacitinib and were sustained 
to month 3 (all p<0.01; figure 3B). Patients who advanced 
from placebo to tofacitinib 5 or 10 mg twice daily at month 3 
reported similar improvement after month 3. The percent-
ages of patients reporting improvements in ASQoL ≥MCID 
were significantly higher for patients receiving tofacitinib 
5 or 10 mg twice daily compared with placebo (figure 2).
Correlation analyses
Correlation analyses of preselected PRO endpoints (based 
on subject matter knowledge and clinical rationale) are 
shown in table 2. Correlations between HAQ-DI and Pain at 
month 3 were high. As expected, EQ-5D-3L pain/discom-
fort and SF-36v2 PF and BP domains were negatively corre-
lated. Pain and SF-36v2 PF and BP domains were moder-
ately (|r|>0.30–≤0.60) or highly (|r|>0.60) negatively corre-
lated with both tofacitinib doses and placebo at month 3.
dIsCussIOn
In this study, TNFi-IR patients with active PsA reported 
improved PROs following treatment with tofacitinib 5 
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Figure 3 (A) Least squares mean (LSM) changes from baseline in Short Form-36 Health Survey version 2 Physical Component 
Summary (SF-36v2 PCS) score and (B) spydergram of domain scores from baseline to month 3 versus age-matched and 
gender-matched norms. (A) *p≤0.05, **p<0.01, compared with placebo; results up to month 3 were based on a repeated 
measures model including data (norm-based) up to month 3 for tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily and 
combined placebo group. Results after month 3 were based on a second repeated-measures model including data up to end 
of study for the four treatment sequences (tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily, placebo → tofacitinib  
5 mg twice daily and placebo → tofacitinib 10 mg twice daily), reporting results after month 3 only. Missing values were not 
imputed. Dashed line indicates end of placebo-controlled period. N represents the number of patients evaluable at each visit. 
(B) *p≤0.05, **p<0.01, ***p<0.001 compared with placebo; spydergrams generated using domain raw scores (range: 0–100); 
US age-gender norms were matched to the protocol population; spydergrams are for illustrative purposes only; p values were 
generated using a repeated-measures model for comparisons with placebo based on LSM changes from baseline in domain 
norm-based scores at month 3 (table 1). Missing values were not imputed. BID, twice daily; BP, bodily pain; GH, general health; 
MH, mental health; PF physical functioning; RE, role emotional; RP, role physical; SF, social functioning; VT, vitality.
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Placebo Placebo → Tofacitinib 5 mg BID Placebo → Tofacitinib 10 mg BID



















































































































Figure 4 Least squares mean (LSM) change from baseline in (A) Functional Assessment of Chronic Illness Therapy-Fatigue 
(FACIT-Fatigue) Total score and (B) Ankylosing Spondylitis Quality of Life (ASQoL). *p≤0.05, **p<0.01, ***p<0.001 compared 
with placebo; results up to month 3 were based on a repeated-measures model including data up to month 3 for tofacitinib 
5 mg twice daily, tofacitinib 10 mg twice daily and combined placebo group. Results after month 3 were based on a second 
repeated-measures model including data up to end of study for the four treatment sequences (tofacitinib 5 mg twice daily, 
tofacitinib 10 mg twice daily, placebo → tofacitinib 5 mg twice daily and placebo → tofacitinib 10 mg twice daily), reporting 
results after month 3 only. Missing values were not imputed. N is the number of patients evaluable at each visit. BID, twice 
daily.
and 10 mg twice daily versus placebo at the first time point 
assessed. Improvements from baseline in these outcomes 
were maintained or improved to month 6. Percentages of 
patients reporting scores ≥normative values and NNTs, 
based on improvements ≥MCID, were generally similar 
in patients receiving tofacitinib 5 and 10 mg twice daily at 
month 3. Further, patients who advanced from placebo to 
tofacitinib 5 or 10 mg twice daily reported improvements 
in similar PROs, based on the repeated-measures models, 
after month 3.
In tandem with this study, a similar analysis was also 
performed in csDMARD-IR TNFi-naive patients with active 
PsA enrolled in the OPAL Broaden RCT (results detailed 
in a separate publication32). This parallel study reported 
clinically meaningful improvements across various PROs 
compared with placebo at month 3, maintained to month 
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Table 2 Correlation analyses of PRO endpoints at month 3
HAQ-DI SF-36v2† PF SF-36v2† BP Pain-VAS EQ-5D-3L P/D
Tofacitinib 5 mg twice daily (N=124) 
  HAQ-DI 1 −0.80 −0.71 0.63 0.55
  SF-36v2† PF – 1 0.70 −0.59 −0.51
  SF-36v2† BP – – 1 −0.78 −0.62
  Pain-VAS – – – 1 0.61
  EQ-5D-3L P/D – – – – 1
Tofacitinib 10 mg twice daily (N=119) 
  HAQ-DI 1 −0.79 −0.72 0.66 0.57
  SF-36v2† PF – 1 0.79 −0.70 −0.52
  SF-36v2† BP – – 1 −0.74 −0.64
  Pain-VAS – – – 1 0.61
  EQ-5D-3L P/D – – – – 1
Placebo (N=117) 
  HAQ-DI 1 −0.81 −0.70 0.62 0.45
  SF-36v2† PF – 1 0.72 −0.63 −0.48
  SF-36v2† BP – – 1 −0.78 −0.63
  Pain-VAS – – – 1 0.61
  EQ-5D-3L P/D – – – – 1
All correlations were ***p<0.001, based on Student’s t distribution (N-2 degree of freedom) to test the null hypothesis of no correlation; 
the analysis included patients with observations at a visit of interest in Full Analysis Set.
†SF-36v2 scores are norm-based.
BP, bodily pain; EQ-5D-3L, EuroQol 5-Dimensions-3-level; HAQ-DI, Health Assessment Questionnaire Disability Index; N, the number of 
patients included in calculating the sample correlation; P/D, pain/discomfort; PF, physical functioning; PRO, patient-reported outcome; 
SF-36v2, Short Form-36 Health Survey version 2; VAS, visual analogue scale.
12, which were similar to those receiving adalimumab. 
Furthermore, NNTs were low across a range of PROs and 
as many as 39% of patients receiving tofacitinib reported 
scores ≥normative values.
Baseline values reported by TNFi-naive patients partic-
ipating in OPAL Beyond were generally worse than those 
in patients in OPAL Broaden.32 Despite these values indi-
cating greater disease activity in patients participating in 
OPAL Beyond, similar improvements were reported in 
PROs in the active treatment groups. Specifically, statis-
tically significant responses were generally observed 
across the same PROs with both tofacitinib doses in both 
RCTs (PtGA; Pain; PGJS, arthritis and psoriasis, arthritis, 
psoriasis; SF-36v2 PCS score, and PF and VT domains; 
FACIT-Fatigue Total score; EQ-5D-3L pain/discomfort 
dimension; EQ-VAS; ASQoL; HAQ-DI). Consistent with 
previously published studies, SF-36v2 domains were illus-
trated by a spydergram to facilitate the assessment of 
multiple domains simultaneously.33 34 This demonstrated 
that the domains were improved compared with base-
line, but were lower than age-gender norms matched to 
the protocol population, with a similar trend observed 
in OPAL Broaden. Furthermore, improvements were 
also broadly similar between OPAL Beyond and OPAL 
Broaden, despite different baseline values.
Some domain scores (SF-36v2 MCS score, and GH, RE 
and MH domains; EQ-5D-3L self-care, usual activities and 
anxiety/depression dimensions) were not significantly 
improved with both tofacitinib doses compared with 
placebo at month 3, implying that there may be no treat-
ment effect on these domains. However, as these improve-
ments were numerically greater, these measures may not 
be sufficiently sensitive to detect small improvements as 
they are generic and not specific to PsA. Additionally, these 
domains (eg, SF-36v2 MCS score, RE, MH) may have larger 
variability than other domains and may require larger 
sample sizes to detect a difference between treatment 
groups.
OPAL Beyond (and OPAL Broaden) are the first tofaci-
tinib studies to examine changes in PROs based on MCID 
and normative values in patients with PsA, both of which aid 
the interpretation of trial data.35 Assessing improvements 
≥MCID and scores ≥normative values offer interpretation 
of their clinical meaningfulness to patients, clinicians and 
policymakers.15 36 Further, NNTs estimate effectiveness by 
determining how many patients must be treated for one to 
receive a benefit.37
Statistically significant improvements ≥MCID were 
evident across a range of PROs in this RCT. Generally, these 
PROs were also significant in the OPAL Broaden study, 
with the exception of FACIT-Fatigue Total score, which was 
significant only in OPAL Broaden.32 SF-36v2 domain score 
improvements ≥MCIDs were reported for both tofacitinib 
doses in PF and BP in both studies. However, different 
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responses were reported in RP, SF and GH domains, where 
RP and SF were significant, compared with placebo, only 
in OPAL Beyond and GH was only significant in OPAL 
Broaden. These changes, across PROs, were also reflected 
by low NNTs; in the current study, NNTs <10 were reported 
across both treatment arms in PtGA, Pain, PGJS (arthritis 
and psoriasis), HAQ-DI, SF-36v2 PCS and four domains 
(PF, RP, BP, SF). This is in general agreement with NNTs in 
the OPAL Broaden study (with the exception of SF [both 
doses] and FACIT-Fatigue Total score [10 mg twice daily]), 
which also demonstrated comparable values to that of 
adalimumab. In both studies, these analyses demonstrate 
the effectiveness of tofacitinib in improving outcomes 
across a range of PROs.32
Establishment of normative values for those without 
chronic conditions allows for further assessment of therapy 
efficacy, providing an objective measure of comparability 
between specific measures in those with and without 
chronic disease. There was a significant change in BP in 
tofacitinib 5 mg twice daily at month 3, demonstrating 
a score comparable to those without arthritis or other 
chronic conditions. This differs from the findings of OPAL 
Broaden, where statistically significant improvements were 
reported in more PROs, specifically: both tofacitinib doses 
in BP and SF; tofacitinib 5 mg twice daily in MCS score; and 
tofacitinib 10 mg twice daily in PCS score, PF, GH and MH. 
This implies that it is possible in some PROs to attain func-
tion comparable to that of the non-disease state. Compar-
ison between these two populations may also imply that 
those who were TNFi-IR are less likely to achieve normative 
scores indicative of a non-disease state.
The reported correlations are similar to previously 
reported correlations between PROs in PsA.38–41 Further-
more, all PROs included in the correlation analysis were at 
least moderately correlated, implying that these improve-
ments are important and consistent with successful 
treatment.
Previous phase III RCTs have detailed the effect of 
specific therapies in patients with PsA.42 43 However, data 
are currently limited and the results of this study demon-
strate the benefit of tofacitinib treatment in this more 
treatment-refractory population. Previous studies have 
shown effect of new therapies on PROs in patients with 
PsA. This study demonstrates that improvement in PROs 
can be achieved with tofacitinib, even in patients who 
had failed to respond to TNFi therapy.
A limitation is that the placebo-controlled period was 
restricted to 3 months. In addition, this RCT population 
did not include individuals from all countries and national-
ities; hence, further studies with more varied patient popu-
lations would be beneficial. Although data are presented 
to month 6, the ongoing long-term extension study will 
delineate long-term effect of tofacitinib across these PROs.
In conclusion, TNFi-IR patients with active PsA who 
received tofacitinib reported clinically meaningful 
improvements in PROs compared with placebo over 
3 months. These improvements were maintained for 
6 months in OPAL Beyond and for 12 months in OPAL 
Broaden.32 The results of these studies provide scientific 
evidence to support decisions regarding clinical therapy 
and further support the use of JAK inhibition as a novel 
mechanism for the treatment of PsA.
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